Browse > Article
http://dx.doi.org/10.4196/kjpp.2016.20.4.379

Effects of analgesics and antidepressants on TREK-2 and TRESK currents  

Park, Hyun (Department of Neurosurgery, Gyeongsang National University Hospital, College of Medicine and Institute of Health Sciences, Gyeongsang National University)
Kim, Eun-Jin (Department of Physiology, College of Medicine and Institute of Health Sciences, Gyeongsang National University)
Han, Jaehee (Department of Physiology, College of Medicine and Institute of Health Sciences, Gyeongsang National University)
Han, Jongwoo (Department of Neurosurgery, Gyeongsang National University Hospital, College of Medicine and Institute of Health Sciences, Gyeongsang National University)
Kang, Dawon (Department of Physiology, College of Medicine and Institute of Health Sciences, Gyeongsang National University)
Publication Information
The Korean Journal of Physiology and Pharmacology / v.20, no.4, 2016 , pp. 379-385 More about this Journal
Abstract
TWIK-related $K^+$ channel-2 (TREK-2) and TWIK-related spinal cord $K^+$ (TRESK) channel are members of two-pore domain $K^+$ channel family. They are well expressed and help to set the resting membrane potential in sensory neurons. Modulation of TREK-2 and TRESK channels are involved in the pathogenesis of pain, and specific activators of TREK-2 and TRESK may be beneficial for the treatment of pain symptoms. However, the effect of commonly used analgesics on TREK-2 and TRESK channels are not known. Here, we investigated the effect of analgesics on TREK-2 and TRESK channels. The effects of analgesics were examined in HEK cells transfected with TREK-2 or TRESK. Amitriptyline, citalopram, escitalopram, and fluoxetine significantly inhibited TREK-2 and TRESK currents in HEK cells (p<0.05, n=10). Acetaminophen, ibuprofen, nabumetone, and bupropion inhibited TRESK, but had no effect on TREK-2. These results show that all analgesics tested in this study inhibit TRESK activity. Further study is needed to identify the mechanisms by which the analgesics modulate TREK-2 and TRESK differently.
Keywords
Analgesics; Background potassium channels; Pain;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet . 2015;386:743-800.   DOI
2 Hall-Flavin DK, Winner JG, Allen JD, Jordan JJ, Nesheim RS, Snyder KA, Drews MS, Eisterhold LL, Biernacka JM, Mrazek DA. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012;2:e172.   DOI
3 Yan J, Dussor G. Ion channels and migraine. Headache. 2014;54:619-639.   DOI
4 Cohen GL. Migraine prophylactic drugs work via ion channels. Med Hypotheses. 2005;65:114-122.   DOI
5 Tsantoulas C, McMahon SB. Opening paths to novel analgesics: the role of potassium channels in chronic pain. Trends Neurosci. 2014;37:146-158.   DOI
6 Kang D, Kim D. TREK-2 (K2P10.1) and TRESK (K2P18.1) are major background $K^+$ channels in dorsal root ganglion neurons. Am J Physiol Cell Physiol. 2006;291:C138-146.   DOI
7 Lafreniere RG, Cader MZ, Poulin JF, Andres-Enguix I, Simoneau M, Gupta N, Boisvert K, Lafreniere F, McLaughlan S, Dube MP, Marcinkiewicz MM, Ramagopalan S, Ansorge O, Brais B, Sequeiros J, Pereira-Monteiro JM, Griffiths LR, Tucker SJ, Ebers G, Rouleau GA. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat Med. 2010;16: 1157-1160.   DOI
8 Pereira V, Busserolles J, Christin M, Devilliers M, Poupon L, Legha W, Alloui A, Aissouni Y, Bourinet E, Lesage F, Eschalier A, Lazdunski M, Noel J. Role of the TREK2 potassium channel in cold and warm thermosensation and in pain perception. Pain. 2014;155:2534-2544.   DOI
9 Acosta C, Djouhri L, Watkins R, Berry C, Bromage K, Lawson SN. TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain. J Neurosci. 2014;34:1494-1509.   DOI
10 Kollert S, Dombert B, Doring F, Wischmeyer E. Activation of TRESK channels by the inflammatory mediator lysophosphatidic acid balances nociceptive signalling. Sci Rep. 2015;5:12548.   DOI
11 Liu P, Xiao Z, Ren F, Guo Z, Chen Z, Zhao H, Cao YQ. Functional analysis of a migraine-associated TRESK $K^+$ channel mutation. J Neurosci. 2013;33:12810-12824.   DOI
12 Mathie A, Veale EL. Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain. Pflugers Arch. 2015;467:931-943.   DOI
13 Wolkerstorfer A, Handler N, Buschmann H. New approaches to treating pain. Bioorg Med Chem Lett. 2016;26:1103-1119.   DOI
14 Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacol Rep 2013;65:1611-1621.   DOI
15 Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015;90:532-545.   DOI
16 Khouzam HR. Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics. Postgrad Med. 2016;128:323-330.   DOI
17 Jesse CR, Wilhelm EA, Nogueira CW. Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. Psychopharmacology (Berl). 2010;212:513-522.   DOI
18 Moore R, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 7:CD008242.
19 Saarto T, Wiffen PJ. Antidepressants for treating neuropathic pain. Cochrane Database Syst Rev 2007:CD005454.
20 Nielsen JC, Bjerring P, Arendt-Nielsen L, Petterson KJ. Analgesic efficacy of immediate and sustained release paracetamol and plasma concentration of paracetamol. Double blind, placebo-controlled evaluation using painful laser stimulation. Eur J Clin Pharmacol. 1992;42:261-264.
21 Mehlisch DR, Sykes J. Ibuprofen blood plasma levels and onset of analgesia. Int J Clin Pract Suppl. 2013;(178):3-8.
22 Baeck SK, Lim MA, Park SY, Lee JS, Lee HS, Koo KS. Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. J Anal Toxicol. 2000;24:271-274.   DOI
23 Laib AK, Brunen S, Pfeifer P, Vincent P, Hiemke C. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. Ther Drug Monit. 2014;36:473-479.   DOI
24 Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 1993;5:322-329.   DOI
25 Paulzen M, Grunder G, Veselinovic T, Wolf B, Hiemke C, Lammertz SE. Duloxetine enters the brain - But why is it not found in the cerebrospinal fluid. J Affect Disord. 2016;189:159-163.   DOI
26 Reis M, Cherma MD, Carlsson B, Bengtsson F. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit. 2007;29:758-766.   DOI
27 Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, Beasley CM. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997;154:963-969.   DOI
28 Brueggemann LI, Mani BK, Mackie AR, Cribbs LL, Byron KL. Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: accounting for cardiovascular side effects and identifying new therapeutic applications. Mol Cell Pharmacol. 2010;2:15-19.
29 Martin DK, Schyvens CG, Wyse KR, Bursill JA, Owe-Young RA, Macdonald PS, Campbell TJ. Role of non-steroidal antiinflammatory drugs (NSAIDs) in modulating vascular smooth muscle cells by activating large-conductance potassium ion channels. Patch Clamp Technique. 2012;14:283-300.
30 Freeman LC, Narvaez DF, McCoy A, von Stein FB, Young S, Silver K, Ganta S, Koch D, Hunter R, Gilmour RF, Lillich JD. Depolarization and decreased surface expression of $K^+$ channels contribute to NSAID-inhibition of intestinal restitution. Biochem Pharmacol. 2007;74:74-85.   DOI
31 Heldestad A, Jonsborg S, Henriksson R, Grankvist K. Acetaminophen protection against estramustine-induced cytotoxicity on cultured fibroblasts. Pharmacol Toxicol. 1998;82:128-131.   DOI
32 Kang D, Kim GT, Kim EJ, La JH, Lee JS, Lee ES, Park JY, Hong SG, Han J. Lamotrigine inhibits TRESK regulated by G-protein coupled receptor agonists. Biochem Biophys Res Commun. 2008;367:609-615.   DOI
33 Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thummler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, Gobbi G, Vaugeois JM, Debonnel G, Lazdunski M. Deletion of the background potassium channel TREK-1 results in a depressionresistant phenotype. Nat Neurosci. 2006;9:1134-1141.   DOI
34 Gotter AL, Santarelli VP, Doran SM, Tannenbaum PL, Kraus RL, Rosahl TW, Meziane H, Montial M, Reiss DR, Wessner K, McCampbell A, Stevens J, Brunner JI, Fox SV, Uebele VN, Bayliss DA, Winrow CJ, Renger JJ. TASK-3 as a potential antidepressant target. Brain Res. 2011;1416:69-79.   DOI
35 Borsotto M, Veyssiere J, Moha Ou Maati H, Devader C, Mazella J, Heurteaux C. Targeting two-pore domain $K^+$ channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept. Br J Pharmacol. 2015;172:771-784.   DOI
36 Kim CW, Choe C, Kim EJ, Lee JI, Yoon SY, Cho YW, Han S, Tak HM, Han J, Kang D. Dual effects of fluoxetine on mouse early embryonic development. Toxicol Appl Pharmacol. 2012;265:61-72.   DOI
37 Semenchuk MR, Davis B. Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. Clin J Pain. 2000;16:6-11.   DOI
38 Vazquez-Gomez E, Arias HR, Feuerbach D, Miranda-Morales M, Mihailescu S, Targowska-Duda KM, Jozwiak K, Garcia-Colunga J. Bupropion-induced inhibition of ${\alpha}$7 nicotinic acetylcholine receptors expressed in heterologous cells and neurons from dorsal raphe nucleus and hippocampus. Eur J Pharmacol. 2014;740:103-111.   DOI
39 Kang D, Han J, Kim D. Mechanism of inhibition of TREK-2 (K2P10.1) by the Gq-coupled M3 muscarinic receptor. Am J Physiol Cell Physiol. 2006;291:C649-656.   DOI
40 Yang Y, Shimomura K, Sakuma K, Maejima Y, Iwasaki Y, Galvanovskis J, Dezaki K, Nakata M, Yada T. Bupropion can close KATP channel and induce insulin secretion. J Pediatr Endocrinol Metab. 2013;26:343-346.
41 Czirjak G, Toth ZE, Enyedi P. The two-pore domain $K^+$ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin. J Biol Chem. 2004;279:18550-18558.   DOI
42 Veale EL, Mathie A. Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels. Br J Pharmacol. 2016;173:1639-1652.   DOI
43 Bang H, Kim Y, Kim D. TREK-2, a new member of the mechanosensitive tandem-pore $K^+$ channel family. J Biol Chem. 2000; 275:17412-17419.   DOI
44 Kang D, Mariash E, Kim D. Functional expression of TRESK-2, a new member of the tandem-pore $K^+$ channel family. J Biol Chem. 2004;279:28063-28070.   DOI
45 Rahm AK, Gierten J, Kisselbach J, Staudacher I, Staudacher K, Schweizer PA, Becker R, Katus HA, Thomas D. PKC-dependent activation of human $K_2p$ 18.1 $K^+$ channels. Br J Pharmacol. 2012;166:764-773.   DOI
46 Enyedi P, Czirjak G. Properties, regulation, pharmacology, and functions of the $K_2p$ channel, TRESK. Pflugers Arch. 2015;467:945-958.   DOI
47 Callejo G, Giblin JP, Gasull X. Modulation of TRESK background $K^+$ channel by membrane stretch. PLoS One. 2013;8:e64471.   DOI
48 Guo D, Hu J. Spinal presynaptic inhibition in pain control. Neuroscience. 2014;283:95-106.   DOI